Shirley Cohen-Mekelburg1, Stephanie Gold2, Yecheskel Schneider3, Madison Dennis2, Clara Oromendia4, Heather Yeo5, Fabrizio Michelassi5, Ellen Scherl3, Adam Steinlauf3. 1. Division of Gastroenterology and Hepatology, New York Presbyterian Weill Cornell Medical Center, New York, NY, 10021, USA. shc9085@nyp.org. 2. Department of Medicine, New York Presbyterian Weill Cornell Medical Center, New York, NY, 10021, USA. 3. Division of Gastroenterology and Hepatology, New York Presbyterian Weill Cornell Medical Center, New York, NY, 10021, USA. 4. Division of Healthcare Policy and Research, New York Presbyterian Weill Cornell Medical Center, New York, NY, 10021, USA. 5. Department of Surgery, New York Presbyterian Weill Cornell Medical Center, New York, NY, 10021, USA.
Abstract
BACKGROUND: Studies have shown that prophylactic biologic therapy can reduce post-surgical Crohn's disease recurrence. AIMS: We aimed to identify the frequency of delay and risk factors associated with a delay in the initiation of prophylactic post-surgical biologic therapy in high-risk patients. METHODS: We performed a cohort study of Crohn's disease patients who underwent a bowel resection. We identified those at risk of recurrence and explored multiple characteristics for those with and without a delay post-operatively. RESULTS: A total of 84 patients were included in our analysis of which 69.0% had a greater than 4-week delay and 56.0% a greater than 8-week delay in post-surgical biologic prophylaxis. Publicly insured patients had a 100% delay in post-surgical prophylaxis initiation (p = 0.039, p = 0.003 at 4 and 8 weeks, respectively). Patients on a biologic pre-surgery were less likely to have a delay (p < 0.001) in post-operative prophylaxis. Care at an inflammatory bowel disease (IBD) center was associated with timely therapy when considering a post-operative immunomodulator or biologic strategy. CONCLUSIONS: There are a substantial number of delays in initiating post-operative prophylactic biologic therapy in high-risk patients. Identifying susceptible patients by insurance type or absence of pre-operative therapy can focus future improvement efforts. Additionally, consultation with IBD-specialized providers should be considered in peri-surgical IBD care.
BACKGROUND: Studies have shown that prophylactic biologic therapy can reduce post-surgical Crohn's disease recurrence. AIMS: We aimed to identify the frequency of delay and risk factors associated with a delay in the initiation of prophylactic post-surgical biologic therapy in high-risk patients. METHODS: We performed a cohort study of Crohn's diseasepatients who underwent a bowel resection. We identified those at risk of recurrence and explored multiple characteristics for those with and without a delay post-operatively. RESULTS: A total of 84 patients were included in our analysis of which 69.0% had a greater than 4-week delay and 56.0% a greater than 8-week delay in post-surgical biologic prophylaxis. Publicly insured patients had a 100% delay in post-surgical prophylaxis initiation (p = 0.039, p = 0.003 at 4 and 8 weeks, respectively). Patients on a biologic pre-surgery were less likely to have a delay (p < 0.001) in post-operative prophylaxis. Care at an inflammatory bowel disease (IBD) center was associated with timely therapy when considering a post-operative immunomodulator or biologic strategy. CONCLUSIONS: There are a substantial number of delays in initiating post-operative prophylactic biologic therapy in high-risk patients. Identifying susceptible patients by insurance type or absence of pre-operative therapy can focus future improvement efforts. Additionally, consultation with IBD-specialized providers should be considered in peri-surgical IBD care.
Entities:
Keywords:
Inflammatory bowel disease; Preventive care; Public payer; Surgery
Authors: P S Morar; O Faiz; J D Hodgkinson; N Zafar; K Koysombat; M Purcell; A Hart; J Warusavitarne Journal: Colorectal Dis Date: 2015-11 Impact factor: 3.788
Authors: Miguel Regueiro; Wolfgang Schraut; Leonard Baidoo; Kevin E Kip; Antonia R Sepulveda; Marilyn Pesci; Janet Harrison; Scott E Plevy Journal: Gastroenterology Date: 2008-10-31 Impact factor: 22.682
Authors: Miguel Regueiro; Fernando Velayos; Julia B Greer; Christina Bougatsos; Roger Chou; Shahnaz Sultan; Siddharth Singh Journal: Gastroenterology Date: 2016-11-10 Impact factor: 22.682
Authors: Stephen B Hanauer; Burton I Korelitz; Paul Rutgeerts; Mark A Peppercorn; Ronald A Thisted; Russell D Cohen; Daniel H Present Journal: Gastroenterology Date: 2004-09 Impact factor: 22.682